About Us

Sichuan Duorui Biopharmaceutical Co., Ltd. was established in 2018, located in Sichuan Province, Chengdu. It focuses on the R&D and

production of Peptide and Oligonucleotide APIs. The main products

include Lanreotide Acetate, Semaglutide, Tirzepatide, and Retatrutide etc.

Covering an area of 300 mu, we leverage cutting-edge peptide synthesis technologies to offer CXO services optimize synthetic routes,enhance R&D efficiency,

and accelerate product commercialization,

thereby driving innovation in the global pharmaceutical industry.

720°VR

Production Quality System

Aug. 2023: "Teriparatide Injection" assembly line passed US FDA site inspection with no 483 observation.

Oct. 2024: "Albuvirtide" API passed the NMPA GMP compliance inspection.

Production Quality System

Capacity in 2026

Workshop: 2 Peptide API Workshop; 1 Veterinary Peptide API Workshop

Capacity: Peptide for Human Use: 500 kg; Peptide for Veterinary Use: 200 kg

Capacity in 2026

Professional Person

160 employees in total:

5 Doctors

32 Master

3 Senior Professional Title

130 Bachelor

Professional and technical personnel account for 92%

Professional Person

Development History



Oct., 2024

"Albuvirtide" API passed the NMPA GMP compliance inspection.

Oct., 2024

Duorui Biopharma & Sinopep Biopharma have reached a strategic cooperation and have officially been renamed Sichuan Duorui Biopharmaceutical Co., Ltd.

Aug., 2023

"Teriparatide" Injection" assembly line passed US FDA site inspection with no 483 observation.

Oct., 2021

Sichuan Frontier Base Opened: Trial production stage of the "Albuvirtide" API

Jul., 2021

The first phase of the Sichuan Frontier Base project has been completed

Aug.,2019

The first phase of the Sichuan Frontier Base project has laid the foundation and started construction

Dec., 2018

Sichuan Frontier Biopharmaceutical Co., Ltd. was registered and established.

Core Advantages

Excellent quality with strong compliance, high capability, competitive pricing, and a stable supply chain.

Quality System

Full-process quality control, passed US FDA international certification

Technological Innovation

Continuous R&D innovation, leading to quick development

Global Layout

Internationalization strategy, serving global customers

High Capability

Peptide for Human use: 500 kg Peptide for Veterinary use: 200 kg